Peer-reviewed veterinary case report
12-week chemo leads to remission in dogs with lymphoma
By Simon, D et al.·Published in Journal of veterinary internal medicine·2006·Department of Small Animal Medicine and Surgery, Germany·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Treatment of dogs with lymphoma using a 12-week, maintenance-free combination chemotherapy protocol.
- Species:
- dog
Plain-English summary
A group of 77 dogs diagnosed with lymphoma underwent a 12-week chemotherapy treatment that did not require ongoing maintenance. The treatment included several medications and resulted in a complete remission rate of 76.3%, with dogs remaining in remission for an average of about 243 days. Most dogs tolerated the treatment well, with only mild side effects reported, and only one dog experienced a serious reaction. This approach shows promise for effectively managing lymphoma in dogs without the need for long-term chemotherapy.
People also search for: dog lymphoma treatment · chemotherapy for dogs · lymphoma remission in dogs · side effects of dog cancer treatment · dog cancer survival rates
Abstract
BACKGROUND: Treatment of lymphoma in dogs by long-term chemotherapy has favorable results. However, the efficacy of short-term, maintenance-free treatment protocols on remission and survival times in dogs has not been determined. HYPOTHESIS: That treatment using a 12-week chemotherapy protocol would be associated with satisfactory treatment outcome in dogs with lymphoma. ANIMALS: 77 dogs with histologically or cytologically confirmed diagnosis of lymphoma. METHODS: Prospective clinical trial in which dogs were treated with a 12-week chemotherapy protocol consisting of L-asparaginase, vincristine, cyclophosphamide, doxorubicin, and prednisolone. RESULTS: Complete remission rate was 76.3%. Multivariate logistic regression analysis revealed that clinical substage (P = .006) and immunophenotype (P = .003) had a significant influence on the likelihood of a dog achieving complete remission. Median duration of first complete remission was 243 days (range 19-1,191 days). The 6-month, 1-year, and 2-year remission rates were 68%, 28%, and 16%, respectively. In the multivariate analysis of patient variables, immunophenotype (P = .022) revealed a significant influence on first remission duration. Toxicosis was mild with the exception of 1 treatment-associated death. CONCLUSIONS AND CLINICAL IMPORTANCE: In this group of dogs the 12-week maintenance-free chemotherapy protocol was well tolerated and had satisfactory results.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/16955821/